SK pharmteco’s Post

In our latest press release, we announced kicking off the year with a new Head of Global Sales and several conference and web events in the first quarter. Azra Benson, a veteran stem cell scientist with extensive commercial experience in the cell and gene therapy space, joins Virica at a time of significant momentum for Virica as customers are looking for solutions to improve the yield of viral vectors and the quality of their cell and gene therapy applications. We also announced several conference highlights for the first quarter: -#ATW2024 nomination for the Disruptive Tech of the Year and a poster presentation -A poster presentation at ECI: Advancing Manufacture of Cell and Gene Therapies VIII -A webinar, Closing the gap: Modelling benefits of AAV scale-up using novel enhancers, hosted by our partners at Cell and Gene Insights (BioInsights) Register Now: https://lnkd.in/ez5Euymk Find more information in our latest Press Release: https://lnkd.in/esAmbq-7 #cellandgenetherapy #viralvectors #viral #viralsensitizers #womeninleadership

Capsida’s David Goertsen, Ph.D., will be presenting at the 4th Next Generation Gene Therapy Vectors Summit, focused on Innovating Gene Therapy Capsid & Payload Design. Dr. Goertsen’s presentation will review Capsida’s progress in AAV capsid engineering to develop gene therapy candidates with improved safety and efficacy profiles for PD-GBA and genetic epilepsy due to STXBP1:   • Platform advancements leading to breakthrough, IV-delivered engineered AAV capsids for the CNS • Generations of directed evolution yielding highly targeted AAV capsids with increased therapeutic index • Potential for Capsida's engineered AAVs to treat neurological disorders across all age groups   This summit brings together more than 60 biopharma leaders, service providers, and academic pioneers to discuss the latest advancements and innovations in vector development for gene therapies.    📅 Event: 4th Next Generation Gene Therapy Vectors Summit  📍 Location: Boston  🗓️ Date: June 14 at 2:15pm   #GeneTherapy #AAV #Biopharma #Capsida #Innovation #NextGenVectorsSummit #NeurologicalDisorders #R&D

🧬 The FDA approved 2 gene edited therapies in December last year! The FDA approved Casgevy and Lyfgenia, two groundbreaking gene therapy treatments for sickle cell disease. Developed by Vertex Pharmaceuticals and Bluebird Bio, respectively, these therapies mark a pivotal moment in medical history! Casgevy, the first FDA-approved CRISPR gene editing therapy, utilizes DNA code to repair damaged cells. Lyfgenia uses cells from the patient’s body to potentially decrease or stop vaso-occlusive events in one treatment. These therapies can replace traditional treatments, including riskier treatment options including bone marrow transplants, by precisely editing faulty genes in stem cells, which could potentially save lives. At QHP Capital, we believe that new gene editing approaches will drive future advancements and treatments in this area. Watch the video below for your industry check-up: #lifesciences #privateequity #celltherapy #geneediting

*We now know Tome Biosciences’s gene editing target* -- From STAT’s Jason Mast: For all the hype surrounding CRISPR, the tool has been largely effective at knocking out genes or making small edits. So when two scientists emerged a couple years ago touting technology capable of inserting large genes into human cells without doing major damage to the DNA, investors agreed to pour over $200 million to try to make it a reality. That round, for Tome Biosciences, was announced in December. On Friday, at a major gene therapy conference (ASGCT), CEO Rahul Kakkar laid out for the first time how the company plans to use the technology: initially to treat a rare disease called phenylketonuria and to design a natural killer cell therapy heavily engineered to safely treat autoimmune diseases. Beyond that are plans to make a heart disease treatment and treatments for rare diseases homocystinuria and hemochromatosis. Full newsletter and coverage here: https://lnkd.in/eJ7v2hKX #geneediting #autoimmune #raredisease

The potential for cell and gene therapies is considered enormous. By targeting diseases at the genetic and cellular level, cell and gene therapies could provide options for people where conventional treatments have failed or where no effective treatment is currently available. In Berlin, Germany, Bayer and Charité - Universitätsmedizin Berlin plan to create a new center for gene and cell therapies to accelerate the availability of these medical advances to patients. This will combine research, development and manufacturing of cell and gene therapies and is a significant step towards an innovative future in healthcare. Construction is expected to start in 2025. Further information can be found here: https://lnkd.in/gCjgGxqH #TeamBayer #Innovation

How are our customers using Maxwell® for cell and gene therapy? ➡ Biodistribution studies for adeno-associated virus (AAV) or lentivirus vector therapy development ➡ Viral genome titer assays in the preclinical phase and/or QC batch release processes to ensure the quality and consistency of lentiviral vectors ➡ In biomarker discovery, gene expression profiling or functional studies to analyze mRNA expression ➡ In vector integration analysis, safety and efficacy evaluation or monitoring gene therapy outcomes to look at transgene copy number ➡ DNA purification to support the development, study of efficacy and manufacturing of CAR-T cell therapies. Find out more about the Maxwell and its Automated Nucleic Acid Extraction for Cell and Gene Therapy Applications ➡️ https://bit.ly/3zcsjFW #CellAndGeneTherapy #assays #CellTherapies #Maxwell #NucleicAcidExtraction #automation #PromegaTechnologies

On the latest episode of “Commercializing Living Therapies with CCRM,” guests Michael May and Matthew Durdy, Cell and Gene Therapy Catapult, explain how public-private partnerships have had an impact in the regenerative medicine sector by advancing cell and gene therapies along the commercialization pathway. In this clip, Michael May speaks about how public-private partnerships work to lower costs and innovate to ensure cell and gene therapies will be accessible to patients. “We have to cut costs to make sure that these are accessible across the board, around the world, to all patients. Costs are high: it’s a new field, these are very complex therapies, they’re still being tested, not just in the clinic but in terms of the supply chain and the delivery of these in the health-care system. The collaboration in public-private partnerships that we’re talking about are going to drive costs down but also invent new ways to deliver these therapies to patients.” Listen wherever you stream podcasts, or at the following link: https://lnkd.in/daTWUkEF  #CCRMPodcast

📢 Cytiva Revolutionizes Gene Therapy Manufacturing with New Cell Lines 📢 Cytiva has introduced new cell manufacturing lines for viral vectors in gene therapies. 🧪 These lines aim to standardize manufacturing, reduce costs, and improve patient access to treatments. 💼 The lines include a transient cell line for speed and flexibility, a packaging cell line for screening genes, and a producer cell line for stable integration of required genes. 💡 Stable cell lines can streamline production and reduce costs for viral vector-based gene therapies. 🔬 Cytiva is also addressing the quality challenge of encapsidated host cell DNA impurities during production. 🚀 The company aims to provide end-to-end solutions for viral vector manufacturing, improving patient access. #BioprocessUpdates #Cytiva #cellmanufacturing #viralvectors #genetherapies #standardize #reducecosts #improvepatientaccess #transientcellline #packagingcellline #producercellline #stablecelllines #streamlineproduction #reducecosts #encapsidatedhostcelldna #endtoendsolutions ▷ Read the full article here: 📎 https://lnkd.in/dPPyDxYU

The potential for cell and gene therapies is considered enormous. By targeting diseases at the genetic and cellular level, cell and gene therapies could provide options for people where conventional treatments have failed or where no effective treatment is currently available. In Berlin, Germany, Bayer and Charité - Universitätsmedizin Berlin plan to create a new center for gene and cell therapies to accelerate the availability of these medical advances to patients. This will combine research, development and manufacturing of cell and gene therapies and is a significant step towards an innovative future in healthcare. Construction is expected to start in 2025. Further information can be found here: https://lnkd.in/ef3VpKDa #TeamBayer #Innovation

The potential for cell and gene therapies is considered enormous. By targeting diseases at the genetic and cellular level, cell and gene therapies could provide options for people where conventional treatments have failed or where no effective treatment is currently available. In Berlin, Germany, Bayer and Charité - Universitätsmedizin Berlin plan to create a new center for gene and cell therapies to accelerate the availability of these medical advances to patients. This will combine research, development and manufacturing of cell and gene therapies and is a significant step towards an innovative future in healthcare. Construction is expected to start in 2025. Further information can be found here: https://lnkd.in/gETgkwgc #TeamBayer #Innovation